Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-02-24
    E.g., 2018-02-24

Articles

171624 items
12:00 AM, Jan 10, 1994  |  BC Week In Review | Clinical News  |  Clinical Results

Betafectin data

At the Hematopoiesis Meeting of The Keystone Symposia on Molecular and Cellular Biology, ABTI (Worcester, Mass.) presented animal data showing that weekly administration of Betafectin significantly enhanced recovery from cyclophosphamide-induced neutropenia in Cebus monkeys. ...
12:00 AM, Jan 10, 1994  |  BC Week In Review | Clinical News  |  Clinical Results

GenSite prenatal genetic testing assay data

APG (Houston) said it has completed the first phase of a multi-phase clinical trial for GenSite. This phase tested a specific component of the test, a DNA probe to detect fetal hemoglobin (HbF). The...
12:00 AM, Jan 10, 1994  |  BC Week In Review | Clinical News  |  Clinical Results

Tuberculosis vaccine data

IDBEF’s ID Vaccine Corp. subsidiary and the University of California at Los Angeles said they have demonstrated protective immunity against Mycobacterium tuberculosis in a guinea pig model. The vaccine consists of purified proteins of M....
12:00 AM, Jan 10, 1994  |  BC Week In Review | Clinical News  |  Clinical Results

CCD 1042 data

COCN (Irvine, Calif.) reported results of a Phase I rising-dose trial conducted in the U.K. in 15 healthy volunteers. As doses increased, investigators saw concomitant increases in plasma levels. Based on the results of the...
12:00 AM, Jan 03, 1994  |  BC Week In Review | Clinical News  |  Regulatory

Affymax N.V. regulatory update

AFMXF (Palo Alto) received a U.S. patent on its peptides and plasmids technology. Patent No. 5,270,170 covers a technique for generating and screening large libraries of random peptides. AFMXF said the technique is useful for...
12:00 AM, Jan 03, 1994  |  BC Week In Review | Company News  |  Deals

Hycor Biomedical deal

HYBD (Irvine, CA) has agreed to acquire for cash Melja Diagnostik GmbH, a diagnostic products company based in Kassel, Germany. HYBD expects to complete the purchase this month. Terms were not disclosed. Melja's sales, principally...
12:00 AM, Jan 03, 1994  |  BC Week In Review | Clinical News  |  Clinical Status

Reticulose anti-viral: Will begin in February a Phase II/III trial

Advanced Viral Reasearch Corp. (ADVR), Miami   Product: Reticulose anti-viral   Indication: Treatment of hepatitis B and hepatitis C   Status: Will begin in February a Phase II/III trial in Argentina in 20 hepatitis C patients and 40...
12:00 AM, Jan 03, 1994  |  BC Week In Review | Clinical News  |  Clinical Status

Bradycor bradykinin antagonist: IND to begin Phase II testing

Cortech Inc. (CRTQ), Denver   Product: Bradycor bradykinin antagonist   Indication: Multiple trauma   Status: The company filed a fourth amendment to its IND to begin Phase II testing in up to 140 patients, to measure effects...
12:00 AM, Jan 03, 1994  |  BC Week In Review | Clinical News  |  Regulatory

Enzo regulatory update

ENZ (Farmingdale, NY) received U.S. Patent No. 5,272,065, covering the regulation of gene activity using genetic antisense technology. The patent covers the use of nucleic acid constructs and the use of transient expression vectors and...
12:00 AM, Jan 03, 1994  |  BC Week In Review | Clinical News  |  Regulatory

Alpha 1 Biomedicals regulatory update

ALBM (Bethesda, Md.) acquired from George Washington University the rights to U.S. Patent No. 5,273,963, which covers methods for treating small cell and non-small cell lung cancers using thymosin. The invention discloses the inhibitory effect...

Pages